A potential approach is to increase the dose of the oral progestogen for four weeks after starting a GLP-1 agonist, and after every dose increase until a stable dose is reached
They are used to: Improve glycemic management in people with diabetes Support weight loss in individuals with overweight or obesity Reduce cardiovascular risk in certain patient populations Most recently, to treat moderate to severe obstructive sleep apnea These medications are typically prescribed at FDA-approved doses and titrated gradually to manage gastrointestinal side effects like nausea, diarrhea, and upset stomach
Rhein has been shown to reduce APAP-induced oxidative damage to the liver cells (Zhao et al., 2011)
The results were striking [1]: At 12 months, women on both semaglutide (Wegovy/Ozempic) and HRT lost 16% of their body weight , compared to 12% in women on semaglutide alone
Retatrutide is a new medicine for weight loss
For those working with compounded formulations, proper handling is essential